Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

NCT00620074

Last updated date
Study Location
Pfizer Investigational Site
Atlanta, Georgia, 30322, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Aspergillosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Patients with invasive aspergillosis for more than 30 days at the time of study entry.
Patients with uncontrolled bacterial or viral infection at the time of study entry.
Patients with significant liver dysfunction or who are taking certain medications which
interact with voriconazole.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AspergillosisAnidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
NCT00531479
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Little Rock, Arkansas
  4. La Jolla, California
  5. LaJolla, California
  6. San Diego, California
  7. San Francisco, California
  8. Gainesville, Florida
  9. Miami, Florida
  10. Atlanta, Georgia
  11. Chicago, Illinois
  12. Chicago, Illinois
  13. Baltimore, Maryland
  14. Baltimore, Maryland
  15. Baltimore, Maryland
  16. Baltimore, Maryland
  17. Detroit, Michigan
  18. Detroit, Michigan
  19. Rochester, New York
  20. Chapel Hill, North Carolina
  21. Winston-Salem, North Carolina
  22. Portland, Oregon
  23. Philadelphia, Pennsylvania
  24. Houston, Texas
  25. Seattle, Washington
  26. Seattle, Washington
  27. Westmead, New South Wales
  28. Herston, Queensland
  29. Adelaide, South Australia
  30. Brugge,
  31. Bruxelles,
  32. Leuven,
  33. Yvoir,
  34. Curitiba, PR
  35. Rio de Janeiro, RJ
  36. Porto Alegre, RS
  37. Winnipeg, Manitoba
  38. Winnipeg, Manitoba
  39. Hamilton, Ontario
  40. Hamilton, Ontario
  41. Montreal, Quebec
  42. Quebec,
  43. Praha 2,
  44. Nantes, Cedex 01
  45. Marseille, Cedex 09
  46. Brest,
  47. Creteil,
  48. GRENOBLE Cedex 09,
  49. Paris,
  50. Rouen Cedex,
  51. Strasbourg,
  52. Berlin,
  53. Berlin,
  54. Bremen,
  55. Dresden,
  56. Frankfurt (Oder),
  57. Hamburg,
  58. Heidelberg,
  59. Homburg/Saar,
  60. Koeln,
  61. Mainz,
  62. Muenchen,
  63. Wuerzburg,
  64. Thessaloniki,
  65. Pune, Maharashtra
  66. Cuneo,
  67. Genova,
  68. Milano,
  69. Milano,
  70. Perugia,
  71. Pescara,
  72. Roma,
  73. Seoul,
  74. Seoul,
  75. Seoul,
  76. Seoul,
  77. Seoul,
  78. RC Leiden,
  79. Lima,
  80. Gdansk,
  81. Warszawa,
  82. Lisboa,
  83. Lisboa,
  84. Moscow,
  85. Moscow,
  86. Moscow,
  87. Saint Petersburg,
  88. Singapore,
  89. Singapore,
  90. Badalona, Barcelona
  91. Madrid,
  92. Madrid,
  93. Salamanca,
  94. Valencia,
  95. Valencia,
  96. Geneve 14,
  97. Lausanne,
  98. Kuei-Shan Hsiang, Taoyuan County
  99. Kaohsiung,
  100. Taipei,
  101. Bangkok,
  102. Bangkok,
  103. Bangkok,
  104. Adana,
  105. Ankara,
  106. London,
  107. Manchester,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
AspergillosisStudy to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
NCT00620074
  1. Atlanta, Georgia
  2. Detroit, Michigan
  3. Fort Worth, Texas
  4. Fort Worth, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AspergillosisVoriconazole For Chronic Bronchopulmonary Aspergillosis
NCT00159822
  1. Nantes, Cedex
  2. Angers Cedex,
  3. Bobigny,
  4. Brest Cedex,
  5. Bris Sous Forges,
  6. Caen Cedex,
  7. Dinan Cedex,
  8. Grenoble Cedex 09,
  9. Lille Cedex,
  10. Lyon Cedex,
  11. Montpellier Cedex 5,
  12. Paris Cedex 18,
  13. Paris Cedex 20,
  14. Paris,
  15. Poitiers Cedex,
  16. Reims Cedex,
  17. Rouen Cedex,
  18. Suresnes,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AspergillosisA Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
NCT00037206
  1. King of Prussia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
Official Title  ICMJE Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment
Brief Summary This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.
Detailed Description The study was terminated on January 12, 2009 due to the overall low rate of enrollment. The decision to terminate the trial was not based on any safety concerns. Patients who were enrolled in the study prior to January 12, 2009 were allowed to remain in the study until completing their participation as specified in the protocol.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Aspergillosis
Intervention  ICMJE
  • Drug: voriconazole
    Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
    Other Name: Vfend
  • Drug: anidulafungin
    Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
    Other Name: Eraxis
Study Arms  ICMJE
  • Experimental: combination 2
    anidulafungin plus voriconazole
    Intervention: Drug: voriconazole
  • Experimental: combination 1
    anidulafungin plus voriconazole
    Intervention: Drug: anidulafungin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: February 9, 2009)
6
Original Estimated Enrollment  ICMJE
 (submitted: February 20, 2008)
50
Actual Study Completion Date  ICMJE February 2009
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.

Exclusion Criteria:

Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries Canada
 
Administrative Information
NCT Number  ICMJE NCT00620074
Other Study ID Numbers  ICMJE A8851014
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP